Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of panobinostat in treating younger
patients with diffuse intrinsic pontine glioma (DIPG). Panobinostat may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Stratum 1 treats patients
with DIPG that has returned or gotten worse (progressed). Stratum 2 treats patients with DIPG
that has not yet gotten worse.
Currently, only Stratum 2 is enrolling patients.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI) Pediatric Brain Tumor Consortium